SCHEMBL29480484

SCHEMBL29480484

OC(c1ccc(-n2cc(-c3ccnc4[nH]cnc34)cn2)nc1)C1CC1

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 2/20 0.35
▸ AURKA O14965 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ INCENP Q9NQS7 1/20 0.33
▸ TPX2 Q9ULW0 1/20 0.33
▸ RIPK2 O43353 1/20 0.33
▸ JAK2 O60674 2/20 0.32
▸ EGLN1 Q9GZT9 1/20 0.31
▸ KDM4A O75164 3/20 0.31
▸ KDM4B O94953 3/20 0.31
▸ KDM5C P41229 3/20 0.31
▸ KDM5B Q9UGL1 3/20 0.31
▸ MELK Q14680 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736238 1.00 GRM4 (0.35) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22735896 0.94 MELK (0.36) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22736196 0.93 KDM4A (0.38) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480606 0.93 KDM4A (0.38) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480547 0.89 JAK2 (0.39) JAK2
SCHEMBL22735736 0.86 JAK2 (0.34) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480633 0.86 JAK2 (0.34) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22736484 0.83 GRM4 (0.35) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480552 0.83 GRM4 (0.35) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480486 0.82 JAK2 (0.34) GRM4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US claimed
CN-114174294-B Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2024-10-25 — — CN claimed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP claimed
CN-114174294-A Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2022-03-11 — — CN claimed
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
CN-114174294-B Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2024-10-25 — — CN disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed
CN-114174294-A Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 GRM4 2623/4885AURKA 222/4885AURKB 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback